{
    "Disease activity (follow up: 6 months; assessed with: DAS28-ESR (Lower values – > benefit) (MCID -1.17)": {
        "No of studies": "3",
        "Study design": "randomised trials",
        "Risk of bias": [
            "very serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": [
            "serious",
            "b"
        ],
        "Imprecision": "not serious",
        "Other considerations": "none",
        "Nº of patients": {
            "MTX monotherapy": "147",
            "LEF": "147"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.1 lower (0.27 lower to 0.07 higher)"
        },
        "Certainty": "⨁⨁◯◯ LOW",
        "Importance": "CRITICAL"
    }
}